Who is sponsoring NCT04413227?

NCT04413227 is sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd..

What drugs are being tested in NCT04413227?

Interventions in NCT04413227: Pegylated Recombinant Human Endostatin（PEG-ENDO）.

What condition does NCT04413227 study?

NCT04413227 studies NSCLC, Solid Tumor.

Is NCT04413227 still recruiting?

NCT04413227 is currently status unknown. Last updated 2 June 2020.

Last reviewed 2020-06-02 · How we verify

NCT04413227

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

Status unknown Phase 1 Last updated 2 June 2020

What this trial tests

Phase 1 trial testing Pegylated Recombinant Human Endostatin（PEG-ENDO） in NSCLC in 30 participants. Status unknown.

Timeline

2 April 2020

Primary endpoint
31 May 2021

30 September 2021

Quick facts

Lead sponsor	Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	2 April 2020
Primary completion	31 May 2021
Estimated completion	30 September 2021
Sites	2 locations across China

Drugs / interventions tested

Pegylated Recombinant Human Endostatin（PEG-ENDO） — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →
Solid Tumor — all drugs for Solid Tumor →

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with NSCLC or Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to examine the safety, tolerability and pharmacokinetics of PEG-ENDO in combination with docetaxel in subjects previously treated or untreated (standard therapy is not suitable or without standard therapy) for advanced or metatatic non-small cell lung cancer (NSCLC) or other solid tumors.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

PEGylated therapeutics in the clinic.
Gao Y, Joshi M, Zhao Z, Mitragotri S. · · 2024 · cited 133× · PMID 38193121 · DOI 10.1002/btm2.10600
Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer.
Haider M, Elsherbeny A, Pittalà V, Consoli V, et al · · 2022 · cited 26× · PMID 35163777 · DOI 10.3390/ijms23031853

Verify or expand the search:

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other Jiangsu Simcere Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07345364 — A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics · Phase 1 · not yet recruiting
NCT07357610 — An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healt · Phase 1 · recruiting
NCT07175233 — A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis · Phase 2 · not yet recruiting
NCT06686745 — Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT06680921 — A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Brea · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04413227 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu Simcere Pharmaceutical Co., Ltd.
Last refreshed: 2 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04413227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing